Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Heinrich

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Leukemia|September 23, 2006
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)M M Schittenhelm, K W H Yee, J W Tyner, et al.
Blood|August 1, 1997
Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cellsR K Rathbun, G R Faulkner, M H Ostroski, et al.
Blood|February 7, 1998
DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint functionM C Heinrich, M E Hoatlin, A J Zigler, et al.
Leukemia|November 6, 2009
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cellsU Rix, L L Remsing Rix, A S Terker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2023
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibC Serrano, S Bauer, D Gómez-Peregrina, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Leukemia|September 23, 2006
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)M M Schittenhelm, K W H Yee, J W Tyner, et al.
Blood|August 1, 1997
Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cellsR K Rathbun, G R Faulkner, M H Ostroski, et al.
Blood|February 7, 1998
DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint functionM C Heinrich, M E Hoatlin, A J Zigler, et al.
Leukemia|November 6, 2009
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cellsU Rix, L L Remsing Rix, A S Terker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2023
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibC Serrano, S Bauer, D Gómez-Peregrina, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 5